Table 2.

Correlation analyses of PRO endpoints at month 3

	HAQ-DI	SF-36v2† PF	SF-36v2† BP	Pain-VAS	EQ-5D-3L P/D
Tofacitinib 5 mg twice daily (N=124)
HAQ-DI	1	−0.80	−0.71	0.63	0.55
SF-36v2† PF	–	1	0.70	−0.59	−0.51
SF-36v2† BP	–	–	1	−0.78	−0.62
Pain-VAS	–	–	–	1	0.61
EQ-5D-3L P/D	–	–	–	–	1
Tofacitinib 10 mg twice daily (N=119)
HAQ-DI	1	−0.79	−0.72	0.66	0.57
SF-36v2† PF	–	1	0.79	−0.70	−0.52
SF-36v2† BP	–	–	1	−0.74	−0.64
Pain-VAS	–	–	–	1	0.61
EQ-5D-3L P/D	–	–	–	–	1
Placebo (N=117)
HAQ-DI	1	−0.81	−0.70	0.62	0.45
SF-36v2† PF	–	1	0.72	−0.63	−0.48
SF-36v2† BP	–	–	1	−0.78	−0.63
Pain-VAS	–	–	–	1	0.61
EQ-5D-3L P/D	–	–	–	–	1

All correlations were ***p<0.001, based on Student’s t distribution (N-2 degree of freedom) to test the null hypothesis of no correlation; the analysis included patients with observations at a visit of interest in Full Analysis Set.

†SF‑36v2 scores are norm-based.

BP, bodily pain; EQ-5D-3L, EuroQol 5-Dimensions-3-level; HAQ‑DI, Health Assessment Questionnaire Disability Index; N, the number of patients included in calculating the sample correlation; P/D, pain/discomfort; PF, physical functioning; PRO, patient-reported outcome; SF-36v2, Short Form-36 Health Survey version 2; VAS, visual analogue scale.